INT98557

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.44
First Reported 2001
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 12
Total Number 13
Disease Relevance 8.42
Pain Relevance 2.56

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (PDE4A) signal transduction (PDE4A) plasma membrane (PDE4A)
nucleus (PDE4A) cytoplasm (PDE4A)
Anatomy Link Frequency
myometrium 1
lung 1
PDE4A (Homo sapiens)
Pain Link Frequency Relevance Heat
headache 8 99.92 Very High Very High Very High
cINOD 3 99.80 Very High Very High Very High
Inflammatory response 6 99.68 Very High Very High Very High
Inflammation 191 98.88 Very High Very High Very High
adenocard 16 95.24 Very High Very High Very High
Nicotine 98 93.60 High High
Arthritis 94 90.12 High High
Inflammatory mediators 20 89.68 High High
rheumatoid arthritis 31 88.48 High High
abdominal pain 4 87.84 High High
Disease Link Frequency Relevance Heat
Toxicity 5 99.72 Very High Very High Very High
INFLAMMATION 218 99.60 Very High Very High Very High
Asthma 40 99.60 Very High Very High Very High
Rhinitis 6 99.16 Very High Very High Very High
Pulmonary Disease 340 98.96 Very High Very High Very High
Disease 55 96.28 Very High Very High Very High
Experimental Arthritis 12 90.12 High High
Rheumatoid Arthritis 32 88.48 High High
Abdominal Pain 4 87.84 High High
Reprotox - General 2 8 87.16 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Besides, because PDE4 activity is high in the amnion and the chorion, we established that not only the myometrium is a target for PDE4 inhibition but also the fetal membranes.
Regulation (target) of PDE4 in myometrium
1) Confidence 0.44 Published 2007 Journal BMC Pregnancy Childbirth Section Body Doc Link PMC1892053 Disease Relevance 0.24 Pain Relevance 0.24
Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs.
Regulation (immunoregulators) of PDE4 associated with inflammation and cinod
2) Confidence 0.43 Published 2002 Journal Curr. Pharm. Des. Section Title Doc Link 12052219 Disease Relevance 0.86 Pain Relevance 0.27
PDE4 as a target in preterm labour

Cyclic nucleotide phosphodiesterases (PDE) are the enzymes catalyzing the hydrolysis and inactivation of the second messengers, cAMP and cGMP.

Regulation (target) of PDE4
3) Confidence 0.27 Published 2007 Journal BMC Pregnancy Childbirth Section Title Doc Link PMC1892053 Disease Relevance 0.41 Pain Relevance 0.17
Similarly, there is some in vitro evidence that inhibition of PDE7 may augment the effects of PDE4 inhibition (Smith et al 2004), although PDE7A inhibitors have little or no anti-inflammatory properties themselves (Giembycz 2005).
Regulation (effects) of PDE4 associated with inflammation
4) Confidence 0.23 Published 2008 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2650605 Disease Relevance 0.65 Pain Relevance 0.24
An alternative strategy to improve the tolerability of PDE4 inhibitors is to develop dual specificity inhibitors that inhibit both PDE4 and either PDE1, PDE3 or PDE7.
Regulation (tolerability) of PDE4
5) Confidence 0.23 Published 2008 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2650605 Disease Relevance 0.49 Pain Relevance 0.18
Reports of a role for PDE4 inhibitors in asthma and COPD treatment [14] together with the known interactions between the MAPK and cAMP pathways [16,17] lead to our interest for possible nicotine-induced changes in PDE4 and cAMP pathway.
Regulation (role) of PDE4 associated with asthma, pulmonary disease and nicotine
6) Confidence 0.23 Published 2010 Journal Respir Res Section Body Doc Link PMC2845563 Disease Relevance 0.66 Pain Relevance 0.36
The effect of PDE4 inhibitors on health status in patients with COPD is variable possibly due to differences in the duration of treatment (Compton et al 2001; Rabe et al 2005; Rennard et al 2006).
Regulation (effect) of PDE4 associated with pulmonary disease
7) Confidence 0.22 Published 2006 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2707800 Disease Relevance 1.02 Pain Relevance 0.16
Long-term studies are required to definitively establish the effects of PDE4 inhibitors on clinical outcomes, including lung function, exacerbation rate, and health status in patients with COPD.


Regulation (effects) of PDE4 in lung associated with pulmonary disease
8) Confidence 0.22 Published 2006 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2707800 Disease Relevance 1.14 Pain Relevance 0.13
RT-PCR experiments and PDE4 activity measurement were performed in order to assess some of the mechanisms that could be involved in desensitization process and we found that neither ADRB2 and ADRB3 mRNA expression levels nor PDE4 activity were affected by salbutamol or SR 59119A treatments.


Neg (neither) Regulation (affected) of PDE4
9) Confidence 0.19 Published 2007 Journal BMC Pregnancy Childbirth Section Body Doc Link PMC1892055 Disease Relevance 0 Pain Relevance 0.07
Inhibition of PDE4 has previously been shown to suppress immune and inflammatory responses, demonstrating PDE4 to be a valid therapeutic target for immune-mediated pathologies.
Regulation (target) of PDE4 associated with inflammatory response
10) Confidence 0.19 Published 2010 Journal Arthritis Res Ther Section Abstract Doc Link PMC2911898 Disease Relevance 1.09 Pain Relevance 0.34
PDE4 was initially chosen as a target in the treatment of airway inflammation due to its expression in the airways [11,12].
Regulation (target) of PDE4 associated with inflammation
11) Confidence 0.19 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2911898 Disease Relevance 1.12 Pain Relevance 0.31
BACKGROUND: The beneficial effects of phosphodiesterase 4 (PDE4) inhibitors in allergic asthma have been shown in previous preclinical and clinical studies.
Regulation (effects) of phosphodiesterase 4 associated with asthma
12) Confidence 0.08 Published 2001 Journal J. Allergy Clin. Immunol. Section Abstract Doc Link 11590377 Disease Relevance 0.36 Pain Relevance 0
The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis.
Regulation (effective) of phosphodiesterase 4 associated with rhinitis and headache
13) Confidence 0.08 Published 2001 Journal J. Allergy Clin. Immunol. Section Title Doc Link 11590377 Disease Relevance 0.38 Pain Relevance 0.10

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox